HARROWCatch this wave 3. I think we are almost finished wave 2 wich is mostly the most extreme. So now i expect the wave 3 is going to start.
−0.75USD
−24.41 MUSD
130.19 MUSD
30.06 M
About Harrow, Inc.
Sector
CEO
Mark L. Baum
Headquarters
Nashville
Website
Employees (FY)
315
Founded
2006
FIGI
BBG010426H87
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
HROW: Can you guess what this pattern is called?See if you can guess it correctly. Earnings on 11/13
Eye Spy a MultibaggerI was hesitant to publish this chart because the extreme upside it shows will likely be viewed as unrealistic. However, HROW recently decisively broke above its 4-year trend channel as business developments have been quite positive lately - particularly with IHEEZO. This is a rare setup where the fu
HROW: Eye Spy A BottomHROW with a nice impulsive, 5-wave move off the low. HROW needs to hold the 0.618 retracement ($18.75) on this pull back, followed by a rally above the $19.95 local peak set today for further confirmation. Very bullish on the long-term prospects of this ticker.
HROW pull back - thoughts?Bounce off of 100 SMA, 2 long bullish candles with lots of volume, plus sound fundamentals. Any thoughts?
HROW - Long Setup Flag Setup with 2020 Insider Buying. Possible entry here or above 8.44., Stop signal 7.83, First target 9.23. 2nd Target Momentum.
Short Term Rise before head and shoulders completion?I see a short term rise in HROW as our current right shoulder of what looks to be a weekly head and shoulders hit a 61.8% Fibonacci retracement level with Stochastic RSI being as oversold as our last oversold areas. I drew two potential rises using some bear rally based Fibonacci Retracments, I feel
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and e
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HROWL is 24.80 USD — it has increased by 0.36% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Harrow, Inc. - 8.625% senior notes due 2026 stocks are traded under the ticker HROWL.
HROWL stock is 1.09% volatile and has beta coefficient of 0.09. Check out the list of the most volatile stocks — is Harrow, Inc. - 8.625% senior notes due 2026 there?
Yes, you can track Harrow, Inc. - 8.625% senior notes due 2026 financials in yearly and quarterly reports right on TradingView.
HROWL stock has risen by 0.49% compared to the previous week, the month change is a 1.00% fall, over the last year Harrow, Inc. - 8.625% senior notes due 2026 has showed a 2.84% increase.
HROWL net income for the last quarter is −9.15 M USD, while the quarter before that showed −4.39 M USD of net income which accounts for −108.34% change. Track more Harrow, Inc. - 8.625% senior notes due 2026 financial stats to get the full picture.
Today Harrow, Inc. - 8.625% senior notes due 2026 has the market capitalization of 372.37 M, it has decreased by 13.82% over the last week.
Yes, HROWL dividends are paid quarterly. The last dividend per share was 0.54 USD. As of today, Dividend Yield (TTM)% is 0%. Tracking Harrow, Inc. - 8.625% senior notes due 2026 dividends might help you take more informed decisions.
Like other stocks, HROWL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Harrow, Inc. - 8.625% senior notes due 2026 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 315.00 employees. See our rating of the largest employees — is Harrow, Inc. - 8.625% senior notes due 2026 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Harrow, Inc. - 8.625% senior notes due 2026 technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Harrow, Inc. - 8.625% senior notes due 2026 stock shows the buy signal. See more of Harrow, Inc. - 8.625% senior notes due 2026 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Harrow, Inc. - 8.625% senior notes due 2026 EBITDA is 12.96 M USD, and current EBITDA margin is 9.92%. See more stats in Harrow, Inc. - 8.625% senior notes due 2026 financial statements.